Mode
Text Size
Log in / Sign up
Phase 3 N=65 Randomized Double-blind Treatment

Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes

Dental Caries

Enrolled (actual)
65
Serious AEs
0.0%
Results posted
Jun 2013
Primary outcome: Primary: Natural Log Transformed Area Under the Fluoride Concentration in Plaque Fluid by Time Curve (AUC) Between 0-4 Hours — 0.54; 0.54 ln(μg*F*minutes/cm^2) — p=0.9762

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Sodium Fluoride (NaF) (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
GlaxoSmithKline
Primary completion
Oct 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Natural Log Transformed Area Under the Fluoride Concentration in Plaque Fluid by Time Curve (AUC) Between 0-4 Hours
0.54; 0.54 0.9762
SECONDARY
Natural Log Transformed AUC for Fluoride Concentration in Plaque Fluid Between 0-4 Hours
0.54; 0.54; 0.05; -0.90 <0.0001 sig
SECONDARY
Change From Baseline in Fluoride Concentration at 15 Minutes After Brushing With Study Treatments
2.00; 1.56; 0.76; 0.03 0.0151 sig
SECONDARY
Change From Baseline in Fluoride Concentration at 30 Minutes Post Brushing With Study Treatments
0.71; 0.72; 0.28; 0.02 0.5545
SECONDARY
Change From Baseline in Fluoride Concentration at 1 Hour Post Brushing With Study Treatments
0.20; 0.22; 0.12; 0.01 0.6865
SECONDARY
Change From Baseline in Fluoride Concentration at 2 Hours Post Brushing With Study Treatments
0.09; 0.09; 0.07; 0.00 0.0783
SECONDARY
Change From Baseline in Fluoride Concentration at 4 Hours Post Brushing With Study Treatments
0.04; 0.04; 0.02; -0.01 0.4309

Summary

The purpose of this study is to investigate the efficacy of different sodium fluoride (NaF) containing toothpastes in prevention of dental caries. Change from baseline fluoride data at various time points up to four hours after a single brushing with NaF containing toothpastes will be evaluated.

Eligibility Criteria

Inclusion Criteria

  • Age:Age 18 through 65 years.
  • General Health: Good general health with (in the opinion of the investigator) no clinically significant and/or relevant abnormalities of medical history or oral examination, specifically including diabetes or hypoglycemia.
  • Compliance: Understands and is willing, able and likely to comply with all study procedures and restrictions.
  • Consent: Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.
  • Oral: a) Currently living in the Indianapolis, Indiana area and not taking fluoride supplements. b) Have a normal stimulated (= 0.8 ml/min) and unstimulated (= 0.2 ml/min) salivary flow rate. c) Have a full complement of natural teeth with the exception of third molars and teeth extracted for orthodontic reasons. Participants natural teeth must have at least one surface free of restoration in each interproximal embrasure. d) Produce at least 6mg of plaque at Screening Visit 2.

Exclusion Criteria

  • Pregnancy: Women who are known to be pregnant or who are intending to become pregnant over the duration of the study. No pregnancy test will be required.
  • Breast-feeding:Women who are breast-feeding.
  • Medical History: Current or relevant history of any serious, severe or unstable physical or psychiatric illness that would make the subject unlikely to fully complete the study or any that increases the risk to the subject.
  • Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
  • Clinical Study/Experimental Medication: Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit 1 at the start of the study with the exception of those participating in GSKCH study Z3170476.
  • Medication: a) Currently taking antibiotics or have taken antibiotics in the two weeks prior to any treatment visit or during the study. b) Has a medical condition that would require prophylactic antibiotics prior to a dental cleaning.
  • Dental: a) Current active caries or moderate to severe periodontal disease that may compromise the health of the participants or the study. b) Current use of chlorhexidine mouthrinse.
  • Personnel: An employee of the sponsor or the study site who is directly involved in the conduct of the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00708305). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search